DelveInsight’s, “Non-Alcoholic Fatty Liver Disease Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the Non Alcoholic Fatty Liver Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Alcoholic Fatty Liver Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Non Alcoholic Fatty Liver Disease Pipeline Report
Request a sample and discover the recent advances in Non Alcoholic Fatty Liver Disease treatment drugs @ Non Alcoholic Fatty Liver Disease Pipeline Outlook Report
Non Alcoholic Fatty Liver Disease Overview
Non-alcoholic fatty liver disease (NAFLD) is a broad term used to cover a spectrum of conditions that are characterized by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis), and absence of secondary causes of hepatic steatosis such as significant alcohol consumption, chronic use of medications that can cause hepatic steatosis or hereditary disorders. The prevalence of NAFLD in western countries is around 20 to 30%.
Non Alcoholic Fatty Liver Disease Emerging Drugs Profile
Find out more about Non Alcoholic Fatty Liver Disease treatment drugs @ Drugs for Non Alcoholic Fatty Liver Disease Treatment
Non Alcoholic Fatty Liver Disease Therapeutics Assessment
There are approx. 80+ key companies which are developing the therapies for Non-Alcoholic Fatty Liver Disease. The companies which have their Non-Alcoholic Fatty Liver Disease drug candidates in the most advanced stage, i.e. phase III include, Inventiva Pharma.
DelveInsight’s Non Alcoholic Fatty Liver Disease pipeline report covers around 100+ products under different phases of clinical development like
Learn more about the emerging Non Alcoholic Fatty Liver Disease pipeline therapies @ Non Alcoholic Fatty Liver Disease Clinical Trials
Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Non Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types such as
Non Alcoholic Fatty Liver Disease Companies
Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, and others.
Dive deep into rich insights for new drugs for Non Alcoholic Fatty Liver Disease Treatment, visit @ Non Alcoholic Fatty Liver Disease Drugs
Scope of the Non Alcoholic Fatty Liver Disease Pipeline Report
For further information on the Non Alcoholic Fatty Liver Disease Pipeline Therapeutics, reach out @ Non Alcoholic Fatty Liver Disease Treatment Drugs
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: yash bhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/